January 20, 2010 at 15:17 PM EST
Free Research: Zacks Report on Teva Pharmaceuticals
Teva Pharmaceutical Industries (TEVA) chief Shlomo Yanai predicts that his generics company can more than double its annual sales to $31 billion by 2015, making it eligible to be one of the top 10 “Big Pharma” companies. Wall Street analysts are mostly bullish on the stock and Moody’s last week boosted the company’s credit rating. [...]
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here